Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
Beam Therapeutics (Nasdaq: BEAM) will present a fireside chat at the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 7, 2022, at 2:55 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) will present a fireside chat at the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 7, 2022, at 2:55 p.m. ET. This session will focus on the company's advancements in precision genetic medicines, particularly its proprietary base editing technology aimed at precise gene modifications. A live webcast will be accessible on Beam's investor website and archived for 60 days. With a strong commitment to innovation and patient care, Beam Therapeutics aims to provide lifelong cures through a diversified portfolio of gene editing programs.
Details
News Market Reaction – BEAM
The recorded move for BEAM in the trading session of this news was +5.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat during the BofA Securities 2022 Virtual Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 2:55 p.m. ET.
A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentations.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.